This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dooley, M A Articles by Falk, R J Search for Related Content PubMed PubMed Citation Articles by Dooley, M A Articles by Falk, R J Social Bookmarking                         What's this?

Immunosuppressive therapy of lupus nephritis

R J Falk

Department of Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina

Aggressive immunosuppressive therapy should be considered for patients with proliferative lupus nephritis as the risk for progression to end stage renal disease is high. Intermittent intravenous cyclophosphamide therapy improves renal survival; longer duration of therapy is associated with fewer relapse of nephritis and decreased risk of diminished renal function. While azathioprine therapy does not differ statistically from steroids alone in prolonging renal survival, this therapy may be considered in patients with few risk factors for progression to renal insufficiency. Methylprednisolone as a single therapy does not prolong renal survival compared with regimens including cyclophosphamide. Plasmapheresis remains under study but has not shown additional benefit in treatment of severe lupus nephritis. The potential roles for cyclosporin A and mycophenylate mofetil in the therapy of proliferative lupus nephritis remain to be defined. Supportive care including rigorous control of hypertension, consideration of angiotensin receptor inhibition or blockade to reduce proteinuria and prolong renal function, control of hyperlipidemia, prevention of osteoporosis, and prevention of pregnancy remain important clinical goals. Current research efforts focus on genetic and socioeconomic factors involved in racial differences in expression of lupus nephritis, hormonal manipulation to preserve gonadal function during cyclophosphamide therapy, and the potential impact on lupus activity of estrogen-containing oral contraceptives or postmenopausal hormone replacement therapy.

Key Words: azathioprine • cyclophosphamide • cyclosporine • mycophenolate mofetil • race

Lupus, Vol. 7, No. 9, 630-634 (1998)
DOI: 10.1191/096120398678920767


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F N Ozdemir, R Elsurer, A Akcay, B H Ozdemir, S Sezer, E Kuscu, and M Haberal Seronegative systemic lupus erythematosus: etiology of nephrotic syndrome and acute renal failure in early postpartum period Lupus, August 1, 2005; 14(8): 629 - 631. [Abstract] [PDF]

				M H Houman, M Smiti-Khanfir, I B. Ghorbell, and M Miled Systemic lupus erythematosus in Tunisia: demographic and clinical analysis of 100 patients Lupus, March 1, 2004; 13(3): 204 - 211. [Abstract] [PDF]